319 related articles for article (PubMed ID: 27442440)
41. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.
Naidoo S; Evans D; Jong E; Mellet K; Berhanu R
S Afr Med J; 2015 Apr; 105(5):393-6. PubMed ID: 26242667
[TBL] [Abstract][Full Text] [Related]
43. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa.
Mokhele I; Jinga N; Berhanu R; Dlamini T; Long L; Evans D
BMC Pregnancy Childbirth; 2021 Jun; 21(1):453. PubMed ID: 34182944
[TBL] [Abstract][Full Text] [Related]
44. "99DOTS"techno-supervision for tuberculosis treatment - A boon or a bane? Exploring challenges in its implementation at a tertiary centre in Delhi, India.
Prabhu A; Agarwal U; Tripathy JP; Singla N; Sagili K; Thekkur P; Sarin R
Indian J Tuberc; 2020 Jan; 67(1):46-53. PubMed ID: 32192617
[TBL] [Abstract][Full Text] [Related]
45. Second-Line Antiretroviral Treatment Outcome in HIV-Infected Patients Coinfected with Tuberculosis in Pakistan.
Shafiq M; Zafar S; Ahmad A; Kazmi A; Fatima A; Mujahid TA; Qazi R; Akhter N; Shahzad A; Rehman SU; Shereen MA; Hyder MZ
Biomed Res Int; 2023; 2023():4187488. PubMed ID: 37124927
[TBL] [Abstract][Full Text] [Related]
46. Provision of antiretroviral therapy for HIV-positive TB patients--19 countries, sub-Saharan Africa, 2009-2013.
Dokubo EK; Baddeley A; Pathmanathan I; Coggin W; Firth J; Getahun H; Kaplan J; Date A
MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(47):1104-7. PubMed ID: 25426652
[TBL] [Abstract][Full Text] [Related]
47. Barriers to and enablers of uptake of antiretroviral therapy in integrated HIV and tuberculosis treatment programmes in sub-Saharan Africa: a systematic review and meta-analysis.
Kadia BM; Dimala CA; Fongwen NT; Smith AD
AIDS Res Ther; 2021 Nov; 18(1):85. PubMed ID: 34784918
[TBL] [Abstract][Full Text] [Related]
48. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy.
Manosuthi W; Kiertiburanakul S; Phoorisri T; Sungkanuparph S
J Infect; 2006 Dec; 53(6):357-63. PubMed ID: 16487593
[TBL] [Abstract][Full Text] [Related]
49. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013.
Norrby M; Wannheden C; Ekström AM; Berggren I; Lindquist L
Infect Dis (Lond); 2018; 50(11-12):807-816. PubMed ID: 30362392
[TBL] [Abstract][Full Text] [Related]
50. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries.
Pettit AC; Jenkins CA; Blevins Peratikos M; Yotebieng M; Diero L; Do CD; Ross J; Veloso VG; Hawerlander D; Marcy O; Shepherd BE; Fenner L; Sterling TR;
J Int AIDS Soc; 2019 Dec; 22(12):e25423. PubMed ID: 31814312
[TBL] [Abstract][Full Text] [Related]
51. Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol.
Naidoo K; Gengiah S; Yende-Zuma N; Padayatchi N; Barker P; Nunn A; Subrayen P; Abdool Karim SS
Implement Sci; 2017 Nov; 12(1):129. PubMed ID: 29132380
[TBL] [Abstract][Full Text] [Related]
52. Impact of antiretroviral and tuberculosis therapies on CD4
Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; La Manna MP; Orlando V; Pinnetti C; Sampaolesi A; Antinori A; Caccamo N; Goletti D
Immunol Lett; 2018 Jun; 198():33-43. PubMed ID: 29635002
[TBL] [Abstract][Full Text] [Related]
53. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales.
Kipp AM; Pungrassami P; Stewart PW; Chongsuvivatwong V; Strauss RP; Van Rie A
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1540-5, i. PubMed ID: 22008770
[TBL] [Abstract][Full Text] [Related]
54. Integration of TB and ART services fails to improve TB treatment outcomes: comparison of ART/TB primary healthcare services in Cape Town, South Africa.
Kaplan R; Caldwell J; Bekker LG; Jennings K; Lombard C; Enarson DA; Wood R; Beyers N
S Afr Med J; 2014 Mar; 104(3):204-9. PubMed ID: 24897825
[TBL] [Abstract][Full Text] [Related]
55. National scale-up of tuberculosis-human immunodeficiency virus collaborative activities in Myanmar from 2005 to 2016 and tuberculosis treatment outcomes for patients with human immunodeficiency virus-positive tuberculosis in the Mandalay Region in 2015.
Theingi P; Harries AD; Wai KT; Shewade HD; Saw S; Win T; Thein S; Kyi MS; Nyunt Oo H; Aung ST
Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):402-409. PubMed ID: 29361150
[TBL] [Abstract][Full Text] [Related]
56. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand.
Akksilp S; Karnkawinpong O; Wattanaamornkiat W; Viriyakitja D; Monkongdee P; Sitti W; Rienthong D; Siraprapasiri T; Wells CD; Tappero JW; Varma JK
Emerg Infect Dis; 2007 Jul; 13(7):1001-7. PubMed ID: 18214171
[TBL] [Abstract][Full Text] [Related]
57. Effect of anti-retroviral therapy on oxidative stress in hospitalized HIV-infected adults with and without TB.
Musisi E; Matovu DK; Bukenya A; Kaswabuli S; Zawedde J; Andama A; Byanyima P; Sanyu I; Sessolo A; Seremba E; Davis JL; Worodria W; Huang L; Walter ND; Mayanja-Kizza H
Afr Health Sci; 2018 Sep; 18(3):512-522. PubMed ID: 30602982
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
59. Measuring the degree of integrated tuberculosis and HIV service delivery in Cape Town, South Africa.
Uyei J; Coetzee D; Macinko J; Weinberg SL; Guttmacher S
Health Policy Plan; 2014 Jan; 29(1):42-55. PubMed ID: 23274439
[TBL] [Abstract][Full Text] [Related]
60. Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection.
Worodria W; Menten J; Massinga-Loembe M; Mazakpwe D; Bagenda D; Koole O; Mayanja-Kizza H; Kestens L; Mugerwa R; Reiss P; Colebunders R;
Antivir Ther; 2012; 17(5):841-8. PubMed ID: 22543224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
